{"id":"oral-anticoagulation-therapy","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Bleeding (major and minor)"},{"rate":"1-3%","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1%","effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Liver enzyme elevation"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oral anticoagulants work through multiple mechanisms depending on the specific agent—vitamin K antagonists inhibit factors II, VII, IX, and X, while direct oral anticoagulants (DOACs) directly inhibit factor Xa or thrombin (factor IIa). These mechanisms prevent the formation of fibrin clots and reduce the risk of thrombotic events in conditions like atrial fibrillation and venous thromboembolism.","oneSentence":"Oral anticoagulation therapy prevents blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:36.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT07496281","phase":"PHASE4","title":"OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2027-03-01","conditions":"Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent","enrollment":2},{"nctId":"NCT07479147","phase":"","title":"SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-12-16","conditions":"Ischemic Stroke, Embolic Stroke of Undetermined Source, Patent Foramen Ovale (PFO)","enrollment":400},{"nctId":"NCT06650501","phase":"PHASE4","title":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT04956978","phase":"NA","title":"Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-06-01","conditions":"Atrial Fibrillation","enrollment":40},{"nctId":"NCT02928497","phase":"NA","title":"Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2017-02-06","conditions":"Stroke","enrollment":481},{"nctId":"NCT04907825","phase":"PHASE4","title":"A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2023-03-13","conditions":"Atrial Fibrillation, Stroke","enrollment":14},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT05900388","phase":"","title":"A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-09-01","conditions":"Venous Thromboembolism, Children Under 2 Years","enrollment":850},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT06863155","phase":"","title":"Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2025-05-06","conditions":"Coronary Artery Disease, Ischemic Heart Disease","enrollment":500},{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT03297281","phase":"NA","title":"Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)","status":"RECRUITING","sponsor":"Clinique Pasteur","startDate":"2017-10-30","conditions":"Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction","enrollment":389},{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT06871228","phase":"NA","title":"Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-08-05","conditions":"Atrial Fibrillation (AF)","enrollment":4100},{"nctId":"NCT07441759","phase":"","title":"throMboembolic Risk Associated To High atrIal Fibrillation riSk","status":"NOT_YET_RECRUITING","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2026-07-06","conditions":"MACE, Atrial Fibrillation (AF), Quality-adjusted Life-years","enrollment":1000},{"nctId":"NCT07441382","phase":"NA","title":"Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-01","conditions":"Atrial Fibrillation (AF), Stroke, Hemorrhage","enrollment":200},{"nctId":"NCT07246005","phase":"PHASE2","title":"LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-12-01","conditions":"Left Ventricular Thrombus","enrollment":120},{"nctId":"NCT07438054","phase":"","title":"PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2026-01-01","conditions":"Atrial Fibrillation (AF)","enrollment":1000},{"nctId":"NCT07432529","phase":"PHASE3","title":"Design and Rationale of the COLT Study","status":"NOT_YET_RECRUITING","sponsor":"Azienda Sanitaria Locale ASL 6, Livorno","startDate":"2026-06-01","conditions":"Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE)","enrollment":940},{"nctId":"NCT07242326","phase":"","title":"SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2025-12-15","conditions":"Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)","enrollment":1000},{"nctId":"NCT07430956","phase":"PHASE3","title":"Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-18","conditions":"Atrial Fibrillation (AF)","enrollment":2628},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT05976685","phase":"NA","title":"Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-05-01","conditions":"Ischemic Stroke, Atrial Fibrillation","enrollment":482},{"nctId":"NCT05836987","phase":"PHASE3","title":"The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-07-13","conditions":"Atrial Fibrillation","enrollment":5350},{"nctId":"NCT07326215","phase":"NA","title":"A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+","status":"RECRUITING","sponsor":"Vantive Health LLC","startDate":"2025-12-11","conditions":"Acute Respiratory Distress Syndrome, Acute Kidney Injury","enrollment":99},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT07404345","phase":"PHASE4","title":"Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)","status":"NOT_YET_RECRUITING","sponsor":"Hospital Civil de Guadalajara","startDate":"2026-03-01","conditions":"Hemodialysis Access Failure, Kidney Disease, End-Stage, Hemodialysis Catheter","enrollment":54},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT05712200","phase":"PHASE3","title":"Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)","status":"RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2022-12-27","conditions":"Atrial Fibrillation (AF)","enrollment":1900},{"nctId":"NCT03907046","phase":"PHASE3","title":"Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","status":"RECRUITING","sponsor":"Yale University","startDate":"2020-01-28","conditions":"Intracerebral Hemorrhage, Atrial Fibrillation","enrollment":700},{"nctId":"NCT06396858","phase":"PHASE4","title":"Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-07","conditions":"Ischemic Stroke","enrollment":4500},{"nctId":"NCT07404436","phase":"PHASE4","title":"Rivaroxaban in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-01-05","conditions":"Idiopathic Membranous Nephropathy","enrollment":134},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":"Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage","enrollment":3500},{"nctId":"NCT07139314","phase":"NA","title":"Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-09-24","conditions":"Ischemic Stroke, Atrial Fibrillation","enrollment":240},{"nctId":"NCT07005024","phase":"PHASE3","title":"DOAC - Dosing Options in AntiCoagulation Prophylaxis","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2025-10-17","conditions":"Cancer, VTE (Venous Thromboembolism)","enrollment":996},{"nctId":"NCT07139301","phase":"NA","title":"Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-09-04","conditions":"Ischemic Stroke, Atrial Fibrillation","enrollment":438},{"nctId":"NCT05156983","phase":"PHASE3","title":"A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-08-24","conditions":"Coagulation Disorder","enrollment":328},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT07330869","phase":"","title":"Warfarin Effects on Male Fertility After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Città di Lecce Hospital, GVM Care & Research","startDate":"2026-02","conditions":"Male Infertility, Heart Valve Disease","enrollment":90},{"nctId":"NCT04258488","phase":"PHASE4","title":"Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement","status":"RECRUITING","sponsor":"Joon Bum Kim","startDate":"2022-02-21","conditions":"AORTIC VALVE DISEASES, Thromboembolism","enrollment":1300},{"nctId":"NCT05838664","phase":"","title":"A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Atrial Fibrillation","enrollment":2140403},{"nctId":"NCT05089227","phase":"PHASE2","title":"Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-02-03","conditions":"Prolonged Anticoagulation, Venous Thromboembolic Disease, Autoimmune Hemolytic Anemia","enrollment":72},{"nctId":"NCT06138184","phase":"NA","title":"Learning Theory Patient Education for Anticoagulants","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2026-04","conditions":"Knowledge, Attitudes, Practice","enrollment":68},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT07185295","phase":"PHASE4","title":"Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Outcomes'10","startDate":"2024-10-18","conditions":"Anticoagulated Patients","enrollment":481},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT06954610","phase":"","title":"Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-11-04","conditions":"Ischemic Stroke, Atrial Fibrillation, Cerebrovascular Disorders","enrollment":500},{"nctId":"NCT04168203","phase":"PHASE4","title":"Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism","enrollment":600},{"nctId":"NCT04755283","phase":"PHASE2","title":"Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2021-02-02","conditions":"Atrial Fibrillation (AF), Stroke","enrollment":1287},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA","enrollment":""},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT07195760","phase":"","title":"Delayed IntraCranial Hemorrhage in Oral AntiCoagulant Treated Patients With Mild Traumatic Brain Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bispebjerg Hospital","startDate":"2023-02-10","conditions":"Head Trauma, Head Injury, Delirium","enrollment":600},{"nctId":"NCT07194811","phase":"","title":"Stroke of Unknown Cause in Women: The Impact of Long-term Heart Monitoring on Stroke Recurrence","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2016-05","conditions":"Cryptogenic Stroke, Atrial Fibrillation, Implantable Cardiac Monitor","enrollment":1400},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT07174778","phase":"NA","title":"Episodic Future Thinking to Improve Anticoagulant Adherence in Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Jiawen You","startDate":"2025-09-15","conditions":"Atrial Fibrillation (AF)","enrollment":68},{"nctId":"NCT06847204","phase":"PHASE1, PHASE2","title":"EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL","status":"COMPLETED","sponsor":"Zaeema Kanwal","startDate":"2025-02-24","conditions":"COVID - 19","enrollment":66},{"nctId":"NCT04298723","phase":"NA","title":"Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.","status":"RECRUITING","sponsor":"Jena University Hospital","startDate":"2020-06-16","conditions":"Intracranial Hemorrhages, Atrial Fibrillation (AF), Atrial Flutter","enrollment":530},{"nctId":"NCT06075628","phase":"","title":"Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","status":"RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2023-07-24","conditions":"Atrial Fibrillation, Ischemic Stroke, Acute","enrollment":100},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT06696079","phase":"NA","title":"Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation","status":"RECRUITING","sponsor":"Rahul Raj","startDate":"2025-07-07","conditions":"Chronic Subdural Hematoma, Atrial Fibrillation (AF)","enrollment":332},{"nctId":"NCT06591741","phase":"NA","title":"PCA Administration in Prosthetic Joint Infection","status":"NOT_YET_RECRUITING","sponsor":"Dr. Dean Reeves Clinic","startDate":"2026-01","conditions":"Prosthetic Joint Infection","enrollment":100},{"nctId":"NCT04483583","phase":"PHASE4","title":"Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2020-12-08","conditions":"Coronary Artery Disease","enrollment":81},{"nctId":"NCT04217447","phase":"PHASE3","title":"Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease","status":"TERMINATED","sponsor":"University Hospital, Brest","startDate":"2020-05-25","conditions":"Coronary Artery Disease","enrollment":874},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT05723926","phase":"NA","title":"Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation","status":"NOT_YET_RECRUITING","sponsor":"Javelin Medical","startDate":"2025-09-20","conditions":"Atrial Fibrillation, Oral Anticoagulation, Stroke","enrollment":2000},{"nctId":"NCT07039604","phase":"","title":"Real-World Study of PADN for the Treatment of PAH","status":"RECRUITING","sponsor":"Pulnovo Medical (Wuxi) Co., Ltd.","startDate":"2025-03-19","conditions":"Pulmonary Hypertension, Hypertension, Pulmonary Arterial","enrollment":200},{"nctId":"NCT07032025","phase":"EARLY_PHASE1","title":"Mechanical Thrombectomy for Acute Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Pulmonary Embolism","enrollment":200},{"nctId":"NCT02387229","phase":"PHASE3","title":"Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2015-03","conditions":"ATRIAL FIBRILLATION","enrollment":1238},{"nctId":"NCT05687448","phase":"PHASE3","title":"DIrect Oral Anticoagulation and Bioprothesis Aortic Valve","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Aortic Valve Disease","enrollment":1500},{"nctId":"NCT03539055","phase":"PHASE4","title":"Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-09-01","conditions":"Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis","enrollment":100},{"nctId":"NCT07006675","phase":"PHASE3","title":"Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial","status":"RECRUITING","sponsor":"Major Extremity Trauma Research Consortium","startDate":"2021-05-26","conditions":"Tibial Fractures, Pain","enrollment":1000},{"nctId":"NCT06523959","phase":"PHASE4","title":"Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial","status":"RECRUITING","sponsor":"Clinical Urology and Epidemiology Working Group","startDate":"2024-06-06","conditions":"Venous Thromboembolism, Bleeding","enrollment":5436},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT05236556","phase":"NA","title":"Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF IV","status":"ENROLLING_BY_INVITATION","sponsor":"University of Massachusetts, Worcester","startDate":"2022-12-15","conditions":"Atrial Fibrillation","enrollment":5094},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT03630055","phase":"PHASE3","title":"Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-10-03","conditions":"Radial Artery Occlusion","enrollment":1800},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT06401863","phase":"NA","title":"Shared Decision for Drug Interactions in Oral Anticoagulation","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-10-01","conditions":"Anticoagulants, Drug Interactions","enrollment":3691},{"nctId":"NCT05351749","phase":"NA","title":"Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan","startDate":"2022-08-01","conditions":"Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation","enrollment":306},{"nctId":"NCT06922240","phase":"PHASE3","title":"Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)","status":"RECRUITING","sponsor":"Suqiao Yang","startDate":"2025-03-21","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":68},{"nctId":"NCT05517265","phase":"","title":"Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"iOMEDICO AG","startDate":"2022-10-12","conditions":"CLL","enrollment":45},{"nctId":"NCT05973240","phase":"","title":"Developing Anticoagulation Self-Report Measure in Adults","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2025-06","conditions":"Adults Undergoing Oral Anticoagulation Therapy","enrollment":305},{"nctId":"NCT06949319","phase":"","title":"Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion","status":"RECRUITING","sponsor":"Nedim Tojaga","startDate":"2024-08-16","conditions":"Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset","enrollment":150},{"nctId":"NCT06922695","phase":"NA","title":"Responding to AF: Pill-in-Pocket Anticoagulation Guided by Automated Monitoring and Alerts","status":"RECRUITING","sponsor":"Oxford University Hospitals NHS Trust","startDate":"2025-04-14","conditions":"Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)","enrollment":50},{"nctId":"NCT06925698","phase":"PHASE3","title":"Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","status":"NOT_YET_RECRUITING","sponsor":"Marmara University","startDate":"2025-04-30","conditions":"Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses","enrollment":110},{"nctId":"NCT03259373","phase":"NA","title":"IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2017-09-25","conditions":"Atrial Fibrillation, Stroke","enrollment":64666},{"nctId":"NCT06598280","phase":"NA","title":"Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Luebeck","startDate":"2025-02-20","conditions":"Atrial Fibrillation","enrollment":270},{"nctId":"NCT04593784","phase":"PHASE2","title":"Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults","status":"TERMINATED","sponsor":"AMAG Pharmaceuticals, Inc.","startDate":"2021-10-13","conditions":"Healthy","enrollment":41},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT04645550","phase":"PHASE4","title":"Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2020-11-22","conditions":"Cirrhosis, Splenectomy; Status, Venous Thrombosis","enrollment":120},{"nctId":"NCT04645537","phase":"","title":"Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2011-07-01","conditions":"Atrial Fibrillation","enrollment":400000},{"nctId":"NCT03302494","phase":"PHASE3","title":"WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2","status":"TERMINATED","sponsor":"Coherex Medical","startDate":"2017-12-27","conditions":"Stroke","enrollment":248},{"nctId":"NCT06869811","phase":"NA","title":"Oral Anticoagulation Versus Left Atrial Appendage Occlusion Added to Direct Oral Anticoagulation in Patients with Stroke Despite Oral","status":"RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2024-07-22","conditions":"Left Atrial Appendage Closure","enrollment":380},{"nctId":"NCT06844227","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)","status":"RECRUITING","sponsor":"McMaster University","startDate":"2021-12-01","conditions":"Atrial Fibrillation (AF)","enrollment":1780},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT05750680","phase":"","title":"DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-05-13","conditions":"Atrial Fibrillation, Thromboembolism, Venous","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1122,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["warfarin or rivaroxaban","Warfarin/Coumadin","New oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban"],"phase":"marketed","status":"active","brandName":"Oral anticoagulation therapy","genericName":"Oral anticoagulation therapy","companyName":"China National Center for Cardiovascular Diseases","companyId":"china-national-center-for-cardiovascular-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral anticoagulation therapy prevents blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}